Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety and effectiveness of the BCL2 inhibitor BGB-11417 in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) in 3 cohorts.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Clinical and definitive histologic diagnosis of WM.

- Meeting ≥ 1 criterion for treatment according to consensus panel criteria from the 2nd
International Workshop on Waldenström's Macroglobulinemia (IWWM).

- Refractory or relapsed disease to the most recent therapy at study entry unless
participants had intolerance to the most recent therapy. Refractory disease is defined
as not attaining at least a major response, or progressing while on or within 6 months
of completing therapy. Relapsed disease is defined as attaining at least a major
response to therapy and meeting the criteria for disease progression beyond 6 months
after completing therapy.

- Adequate organ function.

Exclusion Criteria:

- Central nervous system (CNS) involvement by WM.

- Transformation to aggressive lymphoma, such as diffuse large B-cell lymphoma.

- History of other malignancies ≤ 2 years before study entry.

- Uncontrolled active systemic infection or recent infection requiring parenteral
antimicrobial therapy that was completed ≤ 14 days before the first dose of the study
drug.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 8/29/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Prashant Kapoor, M.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20568795

Mayo Clinic Footer